STOCK TITAN

Boston Scientific Corp. - BSX STOCK NEWS

Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.

Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.

The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.

Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.

Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.

Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.

On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.

Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.

As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.

Rhea-AI Summary

Boston Scientific Corporation has received FDA approval for the fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System, enhancing treatment options for over 10 million people globally with Parkinson's disease. This system includes Bluetooth-enabled, rechargeable, and non-rechargeable implantable pulse generators that work with Cartesia™ Directional Leads for optimal symptom relief. The company plans a controlled U.S. launch following its European debut in September 2020, potentially improving patient access and outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced its agreement to acquire Preventice Solutions for up to $1.225 billion, including $925 million upfront and additional milestone payments. This strategic acquisition aims to enhance Boston Scientific's position in the growing ambulatory cardiac monitoring market, valued at nearly $2 billion. Preventice reported $158 million in net sales for 2020, showing a 30% growth. The deal, expected to close by mid-2021, is projected to be accretive by at least one cent per share in 2022. The acquisition aligns with Boston Scientific's focus on innovative cardiac health solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced the limited release of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) systems. This portfolio includes four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs) that promise personalized pain relief through Fast Acting Sub-perception Therapy (FAST™). Currently, chronic pain affects over 50 million Americans, and traditional therapies can take longer to act. The FDA approved these systems in December 2020, indicating their use in managing chronic intractable pain, including conditions like Complex Regional Pain Syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) reported preliminary fourth-quarter 2020 net sales of approximately $2.71 billion, a decline of about 6.8% year-over-year. For the full year, net sales totaled approximately $9.91 billion, down 7.7%. Key challenges included a significant drop in WATCHMAN™ device sales due to inventory model changes, impacting organic growth by 8% in Q4. Some segments like Peripheral Interventions saw growth (4.8% organic), while Cardiovascular reported a significant decline of 12%. The company expects to discuss these results in detail during upcoming earnings calls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. EST. CEO Mike Mahoney will present, followed by a Q&A session with other executives, including Dan Brennan and Dr. Ian Meredith. On February 3, 2021, the company will hold a webcast at 8:00 a.m. EST to discuss its fourth-quarter financial results, announcing earnings prior to the call. The events will be available for live streaming and replay on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced the sale of its BTG Specialty Pharmaceuticals business to SERB for $800 million in cash. The divestiture aims to enhance the BTG business's potential within specialty pharmaceuticals, particularly in life-saving antidotes. The BTG Specialty Pharmaceuticals is projected to generate $210 million in revenue for 2020. This sale follows the acquisition of BTG for approximately $3.7 billion, resulting in over $1 billion in net proceeds from divested businesses. The transaction is expected to close in H1 2021, pending regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will present at the 2020 Evercore ISI HealthCONx Conference on December 1. The session will feature CEO Mike Mahoney and VP of Investor Relations Susie Lisa, starting at approximately 8:00 a.m. EST. A live webcast and replay of the event will be available at investors.bostonscientific.com, accessible one hour after the session concludes. Boston Scientific is a leader in medical technology, providing innovative solutions that enhance patient care globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Summary

Boston Scientific (BSX) has announced a global voluntary recall of all unused LOTUS Edge Aortic Valve System inventory due to complexities with its delivery system. This recall will not affect patients who already have the valve implanted. The company will retire the entire LOTUS product platform, ceasing all related activities. This decision is estimated to incur pre-tax GAAP charges of $225 million to $300 million, with a significant portion impacting adjusted results. The expected effect on earnings per share for 2021 is a slight increase of 1 to 2 cents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
none
-
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will participate in two virtual investor conferences in November 2020. On November 12, Meghan Scanlon and Susie Lisa will engage in a Q&A session at the Credit Suisse Virtual Healthcare Conference at 8:00 a.m. EST. On November 18, Dan Brennan and Susie Lisa will take part in a Q&A at the Stifel 2020 Virtual Healthcare Conference starting at 8:40 a.m. EST. Live webcasts will be available at investors.bostonscientific.com, with replays accessible an hour after each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
Rhea-AI Summary

Boston Scientific (BSX) has received FDA approval for the Ranger™ Drug-Coated Balloon, aimed at treating peripheral artery disease (PAD) in the superficial femoral and proximal popliteal arteries. With around 200 million affected globally, the Ranger DCB features a low therapeutic drug dose, resulting in high primary patency rates and reduced systemic drug exposure. In pivotal trials, it achieved 94.1% major adverse event freedom and an 82.9% primary patency rate at 12 months, outperforming standard treatments. The device is set to launch in the US following its CE mark in 2014.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags

FAQ

What is the current stock price of Boston Scientific (BSX)?

The current stock price of Boston Scientific (BSX) is $89.86 as of December 23, 2024.

What is the market cap of Boston Scientific (BSX)?

The market cap of Boston Scientific (BSX) is approximately 131.4B.

What does Boston Scientific Corp. specialize in?

Boston Scientific specializes in developing, manufacturing, and marketing medical devices for interventional medical procedures, focusing on less invasive solutions.

What are the main segments of Boston Scientific?

The company operates through two main segments: MedSurg and Cardiovascular.

What recent financial achievement has Boston Scientific announced?

Boston Scientific recently completed a public offering of €2,000,000,000 in notes to finance the acquisition of Axonics, Inc. and to repay existing debt.

What is the AGENT™ Drug-Coated Balloon (DCB)?

The AGENT™ Drug-Coated Balloon is a novel device approved by the FDA to treat coronary in-stent restenosis in patients with coronary artery disease.

What is the focus of Boston Scientific’s latest clinical trials?

The NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System focus on improving patient outcomes and expanding product offerings.

How has Boston Scientific performed financially in 2024?

For the first quarter of 2024, Boston Scientific reported net sales of $3.856 billion, a 13.8% increase from the prior year.

What are some key products manufactured by Boston Scientific?

Boston Scientific manufactures products for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, and more.

How much of Boston Scientific’s sales come from international markets?

Nearly half of Boston Scientific's total sales are from international markets.

Who are Boston Scientific’s customers?

Boston Scientific markets its products to healthcare professionals and institutions globally.

What is Boston Scientific's vision for the future?

Boston Scientific aims to transform lives through innovative medical technologies that improve patient health and reduce healthcare costs.

Boston Scientific Corp.

NYSE:BSX

BSX Rankings

BSX Stock Data

131.40B
1.47B
0.18%
92.6%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MARLBOROUGH